Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Marseille Cedex 5, France Clinical Trials

A listing of Marseille Cedex 5, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (656) clinical trials

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Subjects meeting all inclusion and exclusion criteria will receive lenalidomide lenalidomide will be administered at 10 mg (two 5 mg capsules) once daily on Days 1–21, every 4 weeks. Bone marrow aspirate (baseline and during the course of the study at week 8, 16, 32, 52 and when clinically indicated/for ...

Phase

0.0 miles

Learn More »

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Inclusion of MDS with IPSS low or int-1 and hemoglobin < 10/dL. Study drug: Darbepoetin alfa (Aranesp) 500 microg every two weeks subcutaneously during 12 weeks, combined to filgrastim 300 microg twice weekly for an additional 12 weeks in non responders. Response will be evaluated at 12 weeks. Patients with ...

Phase

0.0 miles

Learn More »

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

OBJECTIVES: Primary - To determine the objective tumor response rate in patients with locally advanced or metastatic papillary renal cell carcinoma treated with sunitinib malate. Secondary - To evaluate the safety of this drug in these patients. - To determine time-to-event variables of overall survival, time to disease progression, time ...

Phase

0.0 miles

Learn More »

Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

OBJECTIVES: Primary - Compare progression-free survival. Secondary - Compare toxicities. - Compare response rate. - Compare overall survival. - Evaluate clinical benefits. - Compare quality of life. - Identify biomarkers that predict therapeutic response. OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms. - ...

Phase

0.0 miles

Learn More »

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Due to anti-arrhythmic pharmacological drugs failure to suppress atrial fibrillation (AF), interest towards preventive pacing treatments is increasing. The importance of this option in the panoply of the preventive tools is fully justified, only by considering the insufficiency, the complexity, or the poor reproducibility of the other non-pharmaceutical approaches. Preventive ...

Phase

0.0 miles

Learn More »

Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives ...

Phase N/A

0.0 miles

Learn More »

Assessment of SpondyloArthritis Society (ASAS) Classification and Diagnostic Criteria for Early Axial Spondyloarthritis (SpA)

Background: Existing criteria for AS/SpA such as mod. New York, ESSG, or Amor criteria for classification and/or diagnosis of spondyloarthritis have limitations when applied to early disease. Moreover, MRI is not part of any of the established criteria and the precise role of MRI in early axial disease has not ...

Phase N/A

0.0 miles

Learn More »

International Collaborative Gaucher Group (ICGG) Gaucher Registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The ...

Phase N/A

0.0 miles

Learn More »

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

The study will capture post-marketing safety data on patients treated with eculizumab. Additionally, the study will collect information on the progression of disease in all patients.

Phase N/A

0.0 miles

Learn More »

Product Surveillance Registry

The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge ...

Phase N/A

0.0 miles

Learn More »